The Potential Role of GLP-1 in Alzheimer’s Disease

Exploring GLP-1’s Potential in Cognitive Health

Research suggests that glucagon-like peptide-1 (GLP-1) receptor agonists, traditionally used for managing diabetes and obesity, could hold therapeutic promise for Alzheimer’s disease (AD). These agents exhibit neuroprotective properties that may address core AD pathologies such as amyloid-beta accumulation, tau hyperphosphorylation, and insulin resistance in the brain (Yıldırım Şımşır et al., 2018; Perry et al., 2004).

It’s important to note that GLP-1 receptor agonists are not currently licensed for the treatment of Alzheimer’s disease. However, ongoing research and clinical trials continue to investigate their potential role (Mullins et al., 2019). If you’d like to discuss this emerging therapy further, book a consultation with one of our specialist nurses.

Click here to book a Microdosing Nurse Discussion Appointment

Mechanisms of GLP-1 in Alzheimer’s Disease

1. Reduction of Amyloid-Beta Levels: GLP-1 analogues have demonstrated the ability to reduce amyloid-beta plaque formation, a hallmark of AD, through improved insulin signalling and reduced oxidative stress (Bak et al., 2011; Perry et al., 2004).
2. Prevention of Tau Hyperphosphorylation: Tau protein hyperphosphorylation disrupts neuron function. GLP-1 activation reduces inflammation and supports mitochondrial health to combat this (Perry et al., 2002; Li, 2007).
3. Improved Brain Insulin Resistance: Insulin resistance in the brain is central to AD pathology. GLP-1 enhances glucose transport across the blood-brain barrier, restoring neuronal function and metabolism (Gejl et al., 2017; Mullins et al., 2019).
4. Neurogenesis and Synaptic Plasticity: GLP-1 supports neurogenesis and synaptic connectivity, key factors in preserving cognitive function (Perry et al., 2004; Abubakar et al., 2024).

Why Microdosing GLP-1 May Be Beneficial

Microdosing involves starting with lower-than-standard doses, gradually titrated to improve tolerability and reduce side effects. For Alzheimer’s patients, this approach offers:

• Minimised Side Effects: Microdosing reduces common gastrointestinal issues like nausea (Bak et al., 2011).
• Better Tolerability: Gradual escalation promotes adherence to the therapy.
• Early Use in High-Risk Groups: Individuals with mild cognitive impairment (MCI) could benefit from early intervention (Li, 2007).

If you would like to discuss any of the content covered in this blog, please book a consultation with our nurse practitioners.

Click here to book a Microdosing Nurse Discussion Appointment

Supporting Evidence

1. Preclinical Models: Animal studies have shown reduced amyloid-beta deposition and improved cognitive performance with GLP-1 therapy (García-Casares et al., 2014; Perry et al., 2002).
2. Clinical Trials: Mullins et al. (2019) demonstrated improved glucose metabolism in the brain with exenatide, although cognitive benefits were not statistically significant.
   Gejl et al. (2017) found that liraglutide prevented decline in brain glucose metabolism.
3. Ongoing Research: Studies are investigating combination therapies, such as GLP-1 agonists with DPP4 inhibitors, to enhance neuroprotection (Abubakar et al., 2024).

Click here to book a Microdosing Nurse Discussion Appointment